Heron Therapeutics (HRTX) Accounts Payables (2010 - 2026)
Heron Therapeutics' (HRTX) quarterly Accounts Payables came in at $9.0 million in Q1 2026, down 27.27% YoY from $12.3 million in Q1 2025, and little changed on a QoQ basis from $9.0 million in Q4 2025.
Heron Therapeutics (HRTX) Accounts Payables (2010 - 2026) Analysis & Trends
Heron Therapeutics (HRTX) has 17 years of Accounts Payables data on file, last reported at $9.0 million in Q1 2026.
- Quarterly Accounts Payables fell 27.27% year-over-year to $9.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $9.0 million (down 27.27% YoY) and the FY2025 annual result came in at $9.0 million, down 23.19% from the prior year.
- Accounts Payables steadied at $9.0 million in Q1 2026, from $9.0 million in the prior quarter.
- In the past five years, Accounts Payables ranged from a high of $13.8 million in Q2 2022 to a low of $363000.0 in Q4 2022.
- A 5-year average of $7.5 million and a median of $9.0 million in 2026 frame the typical range for Accounts Payables.
- Annual changes were most pronounced in 2022 — Accounts Payables sank 90.45% — and 2025, when it soared 1373.48%.
- Tracing HRTX's Accounts Payables over 5 years: stood at $363000.0 in 2022, then soared by 792.56% to $3.2 million in 2023, then soared by 261.39% to $11.7 million in 2024, then declined by 23.19% to $9.0 million in 2025, then dropped by 0.27% to $9.0 million in 2026.
- The last three Accounts Payables figures came in at $9.0 million (Q1 2026), $9.0 million (Q4 2025), and $12.0 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 167.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 470.30 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 108.02 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 622.65 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 428.93 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 35.57 Mn |
| 10 | Heron Therapeutics | 59.96 Mn | 17.29 Mn | 26.09 Mn | 11.64 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 11.64 Mn |
| Mar 31, 2026 | 8.97 Mn |
| Dec 31, 2025 | 8.99 Mn |
| Sep 30, 2025 | 12.02 Mn |
| Jun 30, 2025 | 12.04 Mn |
| Mar 31, 2025 | 12.33 Mn |
| Dec 31, 2024 | 11.71 Mn |
| Sep 30, 2024 | 10.19 Mn |
| Jun 30, 2024 | 10.23 Mn |
| Mar 31, 2024 | 837,000.00 |
| Dec 31, 2023 | 3.24 Mn |
| Sep 30, 2023 | 1.86 Mn |
| Jun 30, 2023 | 1.96 Mn |
| Mar 31, 2023 | 4.07 Mn |
| Dec 31, 2022 | 363,000.00 |
| Sep 30, 2022 | 6.55 Mn |
| Jun 30, 2022 | 13.80 Mn |
| Mar 31, 2022 | 8.23 Mn |
| Dec 31, 2021 | 3.80 Mn |
| Sep 30, 2021 | 5.89 Mn |